China (Mainland)
EMpagliflozin cas 864070-44-0, BI-10773 , (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol CAS NO.864070-44-0
- FOB Price: USD: 100.00-300.00 /Metric Ton Get Latest Price
- Min.Order: 10 Gram
- Payment Terms: L/C,T/T,Other
- Available Specifications:
top (1-10)Metric Tontop (15-30)Metric Tontop (50-80)Metric Ton
- Product Details
Keywords
- EMpagliflozin
- 864070-44-0
- BI-10773
Quick Details
- ProName: EMpagliflozin cas 864070-44-0, BI-1077...
- CasNo: 864070-44-0
- Molecular Formula: C23H27ClO7
- Appearance: White Solid
- Application: Empagliflozin is a novel, potent and s...
- DeliveryTime: 7days
- PackAge: in foil bag or customized
- Port: Tianjin xingang
- ProductionCapacity: 10 Kilogram/Week
- Purity: 99%
- Storage: cool and dry
- Transportation: by air
- LimitNum: 10 Gram
- Moisture Content: less than 0.3%
- Impurity: less than 0.2%
- purity: 99.99%
- water: 0.01%
Superiority
| EMpagliflozin Basic information |
| Product Name: | EMpagliflozin |
| Synonyms: | EMpagliflozin;BI-10773;(1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol;EMpagliflozin/ BI-10773;EMPAGLIFLBZIN;(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-6-(hydroxyMethyl)-tetrahydro-2H-pyran-3,4,5-triol;D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]M ethyl]phenyl]-, (1S)-;(1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol Empagliflozin BI 10773 |
| CAS: | 864070-44-0 |
| MF: | C23H27ClO7 |
| MW: | 450.90928 |
| EINECS: | |
| Product Categories: | API;Inhibitors |
| Mol File: | 864070-44-0.mol |
|
|
|
| EMpagliflozin Chemical Properties |
| bp | 665℃ |
| density | 1.398 |
| Fp | 356℃ |
| Safety Information |
| EMpagliflozin Usage And Synthesis |
| Usage | Empagliflozin is a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. |
Details
| EMpagliflozin Basic information |
| Product Name: | EMpagliflozin |
| Synonyms: | EMpagliflozin;BI-10773;(1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol;EMpagliflozin/ BI-10773;EMPAGLIFLBZIN;(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-6-(hydroxyMethyl)-tetrahydro-2H-pyran-3,4,5-triol;D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]M ethyl]phenyl]-, (1S)-;(1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol Empagliflozin BI 10773 |
| CAS: | 864070-44-0 |
| MF: | C23H27ClO7 |
| MW: | 450.90928 |
| EINECS: | |
| Product Categories: | API;Inhibitors |
| Mol File: | 864070-44-0.mol |
|
|
|
| EMpagliflozin Chemical Properties |
| bp | 665℃ |
| density | 1.398 |
| Fp | 356℃ |
| Safety Information |
| EMpagliflozin Usage And Synthesis |
| Usage | Empagliflozin is a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. |
| EMpagliflozin Basic information |
| Product Name: | EMpagliflozin |
| Synonyms: | EMpagliflozin;BI-10773;(1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol;EMpagliflozin/ BI-10773;EMPAGLIFLBZIN;(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-6-(hydroxyMethyl)-tetrahydro-2H-pyran-3,4,5-triol;D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]M ethyl]phenyl]-, (1S)-;(1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol Empagliflozin BI 10773 |
| CAS: | 864070-44-0 |
| MF: | C23H27ClO7 |
| MW: | 450.90928 |
| EINECS: | |
| Product Categories: | API;Inhibitors |
| Mol File: | 864070-44-0.mol |
|
|
|
| EMpagliflozin Chemical Properties |
| bp | 665℃ |
| density | 1.398 |
| Fp | 356℃ |
| Safety Information |
| EMpagliflozin Usage And Synthesis |
| Usage | Empagliflozin is a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. |